Article Text

Download PDFPDF
What next for the cardiovascular polypill?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The use of fixed-dose combination medicinal products (‘polypills’) for prevention and management of cardiovascular disease (CVD) has been of interest for many years.1,2 However, in contrast with fixed-dose combination products for HIV, tuberculosis and malaria, polypills for CVD have yet to become widely available and no such product is licensed for use in the UK. Two papers recently published in The Lancet have explored the evidence on the effectiveness of polypills and the challenges faced …

View Full Text